Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
BUSINESS
Subcutaneous Vedolizumab Hits Primary Endpoint in PIII: Takeda
Takeda Pharmaceutical said on July 19 that a subcutaneous formulation of vedolizumab met the primary endpoint in a PIII study investigating its efficacy and safety as a maintenance therapy in adult patients with moderately to severely active ulcerative colitis (UC).…
To read the full story
Related Article
- Takeda’s Entyvio SC Form Approved in Europe
May 11, 2020
- Takeda’s Entyvio SC Form Hits Main Goal in PIII Crohn’s Disease Study
February 18, 2020
- FDA Nixes Takeda’s Subcutaneous Entyvio Formulation
December 24, 2019
- Takeda Seeks Japan Approval for Entyvio SC Form
August 9, 2019
- Entyvio SC Form Now under EMA Review: Takeda
April 2, 2019
BUSINESS
- Susaki City to Subsidize Beyfortus Use in Healthy Babies
April 3, 2025
- Ultomiris, Soliris Bolster Labels for gMG in Japan: Alexion
April 3, 2025
- Shionogi Grants Cefiderocol Rights to Clinigen Unit in Australia/New Zealand
April 3, 2025
- Cheplapharm Completes Tarceva Transfer, Announces Hydrea Acquisition in Japan
April 3, 2025
- Boehringer Will Wait and See Impact of Trump Tariffs, FDA Layoffs: CEO
April 3, 2025
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…